Diogo Rau, Chief Information and Digital Officer of Eli Lilly and Company, interviews Dario Amodei, founder and CEO of Anthropic. Amodei discusses Anthropic's enterprise strategy, highlighting its differentiation from consumer AI providers by prioritizing accuracy and reliability over engagement, particularly in fields like drug discovery. He introduces the concept of specialized "Claudes" for various industries, such as financial services and life sciences, which combine inherent model improvements with access to specialized databases. Amodei advises drug discovery professionals to be ambitious with AI adoption, encouraging them to prepare for end-to-end AI integration rather than focusing on incremental changes, to avoid significant delays in bringing benefits to patients.
Sign in to continue reading, translating and more.
Continue
